Pioneering diagnostics
E.g., 24/07/2014
E.g., 24/07/2014

bioMérieux VIRTUO™, the new generation of blood culture system, is CE-marked

VIRTUO™ is the next dimension of blood culture microbial detection

23 July, 2014

Marcy l'Etoile, France, July 23, 2014 - bioMérieux, a world leader in the field of in vitro diagnostics, announces that VIRTUO™, the new generation of BacT/ALERT®, has been CE-marked. This uniquely innovative automated blood culture microbial...

bioMérieux - Second-Quarter 2014 Business Review

17 July, 2014

  • Solid growth in first-half sales
    • Up 7.9%, including BioFire and at constant exchange rates
    • Up 4.2% like-for-like*, in line with the target for the year
    • Up 3.5% on a reported basis
  • Greater...

The General Shareholders’ Meeting of bioMérieux approves the appointment of two new independent directors

28 May, 2014

Marcy l’Etoile, France, May 28, 2014 - The General Meeting of Shareholders of bioMérieux, a world leader in the field of in vitro diagnostics, today approved the appointment of two new independent directors, Agnès Lemarchand and Philippe Gillet.

Agnès...

BioFire’s FilmArray® Gastrointestinal Panel Receives FDA Clearance

05 May, 2014

Marcy l’Etoile, France - May 5, 2014 – bioMérieux, a world leader in the field of in vitro diagnostics, today announced that BioFire, its new molecular biology affiliate, received U.S. Food and Drug Administration (FDA) 510(k) clearance for the FilmArray...

First-Quarter 2014 Business Review

23 April, 2014

  • Sales:
    • Up 7.9%, including BioFire and at constant exchange rates
    • Up 4.1% like-for-like*, in line with the target for the year
      • Continued stabilization in Western Europe, up 1.4%*
      • ...

Alexandre Mérieux Assumes Role of bioMérieux CEO

15 April, 2014

Marcy l’Etoile (France), April 15, 2014 - Alexandre Mérieux will take on the role of Chief Executive Officer of bioMérieux and head its Management Committee. To step up the rollout of its strategic plan, a new organization is being deployed.

The...

bioMérieux - 2013 Financial Results

19 March, 2014

HIGHLIGHTS

Objectives met

  • Solid financial performance
  • Sales up 4.6% at constant exchange rates and scope of consolidation
  • Operating income before non-recurring items: €262 million, or 16....

bioMérieux strengthens its Clostridium difficile offer with the launch of VIDAS® C. difficile GDH

VIDAS® C. difficile GDH is the 100th assay for use on VIDAS® range VIDAS® C. difficile GDH is the only FDA-approved automated immunoassay parameter for GDH* detection * Glutamate dehydrogenase

26 February, 2014

Marcy l'Étoile, France, February 26, 2014 - bioMérieux, a world leader in the field of in vitro diagnostics, is pleased to announce that the launch of VIDAS®C. difficile GDH makes it the only company with the width to provide...

BioFire Submits 510(k) Application to FDA for FilmArray® Gastrointestinal Panel

19 February, 2014

BioFire Diagnostics, LLC today announced that it has submitted the FilmArray Gastrointestinal (GI) Panel to the U.S. Food and Drug Administration (FDA) for 510(k) clearance. The comprehensive FilmArray GI Panel tests for over 20 common bacteria, viruses and parasites that cause infectious...

Appointment of Claire Giraut as bioMérieux’s Corporate Vice President & Chief Financial Officer

27 January, 2014

Marcy l’Etoile, France, January 27, 2014 bioMérieux, a world leader in the field of in vitro diagnostics, announces that Claire Giraut has been appointed Corporate Vice President & Chief Financial Officer.

Claire Giraut...